高危局限性前列腺癌GETUG-12试验的无复发生存建模与竞争风险分析
基于GETUG-12 III期随机对照试验的前瞻性数据,比较ADT单用与ADT联合多西他赛和雌莫司汀在高危局限性前列腺癌中的复发模式。413例患者随机分组,采用参数生存模型分析RFS,竞争风险方法分析生化进展后第二事件。结果显示从随机化到生化进展的时间间隔是局部或远处复发的主要预后因素。
要点
- 分段指数模型(0-3年与≥3年)最佳刻画RFS,风险因素和治疗无时间依赖性效应。
- 生化进展距随机化≥3年者第二事件风险显著低于<3年者(HR 0.49,95%CI 0.30-0.79)。
- 竞争风险分析中该时间间隔对转移有显著保护作用(sub-HR 0.41,95%CI 0.23-0.73)。
核心结论
- 从随机化到生化进展的时间间隔是高危局限性前列腺癌患者发生局部或远处复发的主要预后因素。
研究设计与样本
- GETUG-12 III期随机对照试验的前瞻性数据,2002至2006年随机413例患者,206例接受ADT,207例接受ADT联合多西他赛和雌莫司汀(DE),均加局部治疗。
- RFS为主要终点,采用参数生存模型分析;从生化进展定义的第二无事件生存(SEFS)采用竞争风险方法分析。
主要发现
- 分段指数模型含两个时间区间([0-3[;≥3年)最佳刻画RFS,风险因素和治疗无时间依赖性效应。
- 限定于发生生化进展的患者,从随机化到生化进展时间间隔≥3年者第二事件风险显著低于<3年者(HR 0.49,95%CI 0.30-0.79)。
- 竞争风险分析中,该时间间隔对转移有显著保护作用(sub-HR 0.41,95%CI 0.23-0.73),已考虑挽救治疗。
临床怎么用
- 对于高危局限性前列腺癌患者,生化进展距随机化时间间隔可作为复发风险分层的重要参考。
- 时间间隔≥3年的生化进展患者第二事件及转移风险较低,或可指导后续随访与治疗决策。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen-deprivation therapy (ADT) plus radiotherapy is a standard of care for men with high-risk localized prostate cancer (PC). Adding docetaxel in this setting demonstrated better relapse-free survival (RFS) but not survival. Few data are available on relapse patterns. Our aim was to investigate whether different patterns of relapses exist in men with high-risk localized PC. PATIENTS AND METHODS: Prospective data from the GETUG12 phase 3 randomized controlled trial comparing ADT alone vs ADT + docetaxel and estramustine (DE) was examined. RFS (main endpoint) was analysed using parametric survival models and second event-free survival (SEFS) defined from biochemical progression (BP) was analysed using a competing-risk approach. RESULTS: Overall, 413 patients were randomized from 2002 to 2006, 206 treated with ADT and 207 with ADT+DE, in addition to local treatment. First analysis showed that the piecewise-exponential model with two time-intervals ([0-3[; ≥3 years) was the model that best characterized RFS with no time-dependent effect of risk factors and treatment. Second analyses limited to patients with a BP showed that the risk of a second event was significantly lower in patients with a longer time-interval from randomization to BP (hazard ratio (HR≥ 3 versus < 3 years): 0.49 [95% CI 0.30-0.79]). In competing-risk analysis, a significant and protective effect of this time-interval was observed for metastases (sub-HR≥ 3 versus < 3 years: 0.41 [0.23-0.73] accounting for salvage treatment. CONCLUSION: Time-interval from randomization to BP is a major prognostic factor for developing local or distant recurrences for patients with high-risk localized PC.
引用
- Vicier C, Erdogan F, Allouache N, et al. Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12. Eur J Cancer. 2026. PMID: 41855781. doi:10.1016/j.ejca.2026.116678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。